Genomenon and OmniTier Partner to Bring Mastermind’s Evidence Sources to CompStor Insight

Genomenon, Inc., an AI-driven genomics company, announced a partnership with OmniTier, which includes integration of the Mastermind Genomic Search Engine into their on-premises based CompStor Insight genomics analysis platform. This integration will allow CompStor users to preview the number of published articles related to their search and easily link out to view the evidence in Mastermind.

OmniTier’s CompStor genomics analysis platform utilizes proprietary MACS (Memory-Accelerated Compute and Storage) technologies to accelerate both secondary and tertiary analysis on standard CPU hardware without the need for GPUs or FPGAs, which are expensive and technically challenging to support. Locating secondary and tertiary analysis on-premises rather than in the cloud allows organizations to benefit from up to a 75% reduction in patient data storage costs, as well as greater control and security over their data. Additionally, OmniTier has shown that in using CompStor’s automated workflows, genomics centers can increase the number of patients that can be analyzed by 50-100X, compared with manual based analysis.

CES 2022 News: Vuzix and TeamViewer to Jointly Demonstrate Frontline AR Platform for Connected Workers at CES 2022

“Our customers have been asking us to partner with Genomenon to give them access to the world’s most comprehensive source for genomic variant literature.” said Dr Hemant Thapar, CEO of OmniTier. “With this partnership, we will bring the power of Mastermind variant evidence lookup to CompStor’s fast, low cost, on-premises based variant interpretation, designed to expand genomic screening at an affordable cost.”